AstraZeneca (LSE:AZN) recently announced positive developments regarding TAGRISSO®'s survival benefits in treating non-small ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. AstraZeneca PLC stands fifth on our list among the most ...

In the last reported quarter, U.S. sales of Keytruda were negatively impacted by around $250 million due to the timing of ...

I was diagnosed with breast cancer, then lung cancer 17 years later — and both ultimately led me to make meaningful, positive ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...

Non-Small Cell Lung Cancer Market grows as immunotherapy approvals by Merck & Bristol-Myers reshape global treatment pathways. Anurag Tiwari Orion Market Research Pvt Ltd +91 91798 28694 email us here ...

Cambridge: AstraZeneca has received approval for Imfinzi (durvalumab) in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

AstraZeneca announces positive results from FLAURA2 phase III trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, July 22, 2025, ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been approved by the European Commission (EC) to treat resectable muscle-invasive bladder cancer (MIBC).